Introduction {#sec1_1}
============

The success of glaucoma drainage devices depends on the characteristics of the fibrous capsule that forms around the end plate that starts growing just after placement in the subconjunctival space \[[@B1]\]. While thin capsules predict lower postoperative intraocular pressure (IOP) levels, a lower IOP is not always better and chronic hypotony (IOP \<5 mm Hg) should be avoided. We present three cases with prolonged postoperative hypotony and the relation with immunosuppressive therapy.

Findings {#sec1_2}
========

Case Report 1 {#sec2_1}
-------------

A 44-year-old Caucasian woman with juvenile rheumatoid arthritis treated with methylprednisolone 10 mg/24 h for 20 years was referred because of chronic refractory glaucoma in her right eye (RE) (visual acuity, 20/25). The IOP was 24 mm Hg with high fluctuations despite timolol/dorzolamide and brimonidine twice daily. The corneal thickness was 490 μm. The cup/disc ratio was 0.9 with a severely affected visual field. In February 2008, a non-valved implant (Triple Acri.Tec, Acri.Tec GmbH, Berlin, Germany) (fig [1](#F1){ref-type="fig"}) with a 6/0 polyglactin ligature was placed over the two superior quadrants. Postoperative treatment with topical dexamethasone (1 mg/ml)-tobramycin (3 mg/ml) and ciprofloxacin (3 mg/ml) was started along with her long-term preoperative systemic methylprednisolone. The IOP values decreased below 5 mm Hg with the spontaneous release of the ligature 1 month later, and a spontaneous leakage through the conjunctival surgical suture was noticed (fig [2](#F2){ref-type="fig"}). The eye remained quiet with no signs of inflammation; surgical closing of the leakage was necessary. The IOP remained below 5 mm Hg for 4 months with no leak; therefore, we explanted one of the two plates. The IOP remained low during the following month, so oral methylprednisolone was withdrawn and the non-valved implant was replaced with a FP7 Ahmed valve (New World Medical Inc., Rancho Cucamonga, Calif., USA). After replacement, the IOP remained stable at 10--12 mm Hg. Histologic examination of the capsule showed irregular loose tissue with thicknesses ranging from 0.02 to 0.12 mm depending on the area studied (fig [3](#F3){ref-type="fig"}).

Case Report 2 {#sec2_2}
-------------

A 22-year-old Caucasian man with traumatic aphakia, aniridia, and immune-rejected penetrating keratoplasty (PK) in his RE was referred because of uncontrolled advanced glaucoma. The left eye (LE) was normal. The IOP in his RE was 62 mm Hg on maximal tolerated hypotensive medications. He had been taking oral prednisolone for 1 year. One day later, a double-plate Molteno implant (Molteno Ophthalmic Ltd., Dunedin, New Zealand) with a 6/0 polyglactin ligature and anterior vitrectomy were performed. Postoperative treatment with topical dexamethasone (1 mg/ml)-tobramycin (3 mg/ml) and ciprofloxacin (3 mg/ml) was started along with his previous oral prednisolone. Ten days later, another PK and a complete pars plana vitrectomy were performed, and a sulcus fixation intraocular lens was implanted for aniridia. Systemic immunosuppression, i.e., 150 mg of cyclosporine and 1 g of mycophenolate mofetil, was added to the treatment. On day 24 after shunt implantation, spontaneous release of the absorbable ligature provoked severe hypotony, with leaking dehiscence that was repaired. Because the hypotony lasted for 2 months, we tapered the immunosuppressive treatment with no response. The IOP remained below 5 mm Hg, so the double Molteno implant was replaced with a FP7 Ahmed valve. Macroscopically, the capsular tissue was thin and irregular (fig [4](#F4){ref-type="fig"}). The pathology examination showed irregular areas of loose collagen tissue with thicknesses of 0.02, 0.18, and 0.6 mm. The IOP recovered to the low teens and another PK with administration of systemic immunosuppressant was performed 6 months later.

Case Report 3 {#sec2_3}
-------------

A 15-year-old Iranian girl diagnosed with bilateral glaucoma secondary to the Axenfeld-Rieger syndrome was referred in January 2012 because of uncontrolled IOP in the LE. The glaucoma was medically controlled in the RE. The LE visual acuity was counting fingers and the IOP was 44 mm Hg with maximal tolerated topical treatments and acetazolamide 250 mg/8 h. Slit-lamp examination of the LE showed an edematous cornea that prevented further examination. The lens and iris diaphragm were attached to the cornea. A previously implanted Ahmed capsule bulged through the superonasal conjunctiva. On January 30, a pars plana vitrectomy with lensectomy through an Eckhard prostheses and a PK along with a first-stage Baerveldt-350 implant (Abbott Medical Optics, Abbott Park, Ill., USA) were performed. Immunosuppressive therapy was started with oral prednisone 60 mg/24 h and cyclosporine 10 mg/12 h along with topical dexamethasone (1 mg/ml)-tobramycin (3 mg/ml) and ciprofloxacin (3 mg/ml). After returning to Iran, the patient came back 48 days later without tapering the systemic steroids as instructed. The eye was quiet and the new cornea allowed good fundus and anterior segment visualization; the second stage of drainage implant surgery was performed and the intraocular portion of the tube was placed in the superonasal quadrant in the posterior chamber. During surgery, we visualized the aqueous humor flowing freely from the implant plate due to the absence of the capsule. A 6/0 polyglactin ligature around the tube was placed to avoid postoperative hypotony. The cyclosporine and oral prednisone were tapered.

Discussion and Importance {#sec1_3}
=========================

The capsular thickness and permeability around drainage devices determine the rate of aqueous outflow. During the early postoperative period, the inflammatory and fibrovascular response in the growing capsule determines its histologic structure. Systemic corticosteroids have been previously reported to cause thinning of implant capsule \[[@B2]\], and the use of oral prednisone along with flufenamic acid due to their anti-inflammatory effect in the capsule \[[@B3]\] has been advised for preoperative and postoperative therapy to decrease the final wall thickness, thus increasing its permeability \[[@B4]\]. Additional prospective studies have not demonstrated the benefits of adjuvant anti-inflammatory and antimitotic treatments, although some indirect observations have shown some inhibitory effect on the capsular formation \[[@B5]\]. In 2003, Molteno et al. \[[@B6]\] reported the histologic characteristics of the early fibroproliferative response and the later fibrodegenerative response in capsules that formed around Molteno implants. The authors observed thinner capsules in patients receiving long-term systemic prednisone, diclofenac, and colchicine. Ceballos et al. \[[@B7]\] and Da Mata et al. \[[@B8]\] reported persistent hypotony in four uveitic eyes after Baerveldt-350 and Ahmed valve surgery. No clear etiopathogenesis of this complication was described. The current patients had been receiving long-term oral immunosuppressive treatment during the early postoperative period, when the capsules were forming. In case 1, the patient had been taking oral methylprednisolone for 20 years, and in case 2, the anti-inflammatory effect of oral prednisolone for 1 year was increased as a result of the newly introduced immunosuppressive drugs. In case 3, the patient had taken an overdose of prednisolone along with the immunosuppressive therapy for more than 1 month. In all cases, the resulting capsules were macroscopically irregular and thin, leading to leaking and hyperfiltration. The current results indicate that glaucoma surgeons should be aware of systemic treatments that might alter the scarring process when planning a tube surgery. It seems reasonable to suggest that in these cases, valved implants might better maintain IOP levels within normal ranges, thus avoiding dangerous chronic postoperative hypotony.
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![**a** The Triple Acri.Tec implant is a triple plate implant made of hydrophobic polydimethylsiloxane. The silicon disc measures 11.7 mm in diameter with 0.3 mm of total thickness. The silicon tube is attached to the central plate, and has a lumen of 0.25 mm and an outer diameter of 0.64 mm. It can be customized to one, two or three plates. **b** In case 1, the implant was customized for two plates.](cop-0007-0132-g01){#F1}

![Case 1. Just after the spontaneous release of the ligature, aqueous leakage was noticed over the conjunctival suture below the second superotemporal plate of the Acri.Tech implant (arrow).](cop-0007-0132-g02){#F2}

![Case 1 (hematoxylin and eosin, ×20). The capsule at 5 months postoperatively. The inner wall is comprised of hyalinized fibrosis (0.02 mm) and outer layer of edematous collagen tissue (0.04 mm).](cop-0007-0132-g03){#F3}

![Case 2. A macroscopic specimen shows the surgically excised capsule, which is irregular with extremely thin areas (\*).](cop-0007-0132-g04){#F4}
